Shanna Miranti, MPAS, PA-C

Managing Pediatric AD With New Topicals

Panelists discuss how new nonsteroidal treatments are transforming the management of pediatric atopic dermatitis (AD) by combining efficacy, safety, and convenience. Simplified regimens encourage better adherence, while gentle formulations support long-term use without irritation or systemic risks.

They emphasize the role of caregiver education—teaching families how to maintain treatment routines and address flares early helps sustain progress. Consistent communication builds trust and improves outcomes, allowing children to live more comfortably and confidently.

Panelists conclude that integrating innovative therapies with supportive care strategies creates a balanced, sustainable approach to managing chronic AD in young patients.




Videos

Panelists discuss how new nonsteroidal therapies improve adherence, comfort, and long-term skin health for children with AD.

Ruxolitinib Efficacy and Safety in Pediatric AD

Panelists discuss how newer studies exploring JAK-targeting creams for children with mild to moderate atopic dermatitis (AD) demonstrate encouraging efficacy and sustained response. Many patients experience visible improvement and reduced itch within weeks, with benefits maintained over time.

Panelists also highlight favorable safety profiles, noting that adverse effects are generally mild and limited to the treatment area. These outcomes support expanding nonsteroidal options for children, reducing reliance on corticosteroids for long-term control.

Caregiver feedback reinforces the value of well-tolerated, easy-to-apply therapies that integrate smoothly into daily life, enhancing consistency and confidence.



Panelists discuss how JAK-targeting topical therapies offer effective, well-tolerated solutions for children with mild to moderate AD.

Roflumilast Efficacy and Safety in Pediatric AD

Panelists discuss how recent research has evaluated nonsteroidal topical agents for mild to moderate pediatric atopic dermatitis (AD), showing encouraging results for safety, tolerability, and durability. These findings suggest that effective inflammation control can be achieved with minimal irritation or adverse effects.

They highlight the importance of meaningful measures—such as itch reduction, body surface area improvement, and quality-of-life scores—to guide treatment decisions. These patient-centered outcomes help clinicians tailor therapies to what matters most for families.

Panelists emphasize that as research continues, these data-driven insights will refine treatment approaches and support individualized care for every child.

Panelists discuss how evidence from clinical studies supports the safety and effectiveness of new nonsteroidal treatments for children with AD.

Systemic Absorption and Dosing in Pediatric AD

Panelists discuss how minimal systemic absorption is a key factor in choosing therapies for children with atopic dermatitis (AD). Treatments that act locally on the skin reduce risk of internal adverse effects, providing reassurance for families and clinicians alike.

Once-daily regimens also lessen caregiver burden by making routines easier to maintain. Simplifying dosing schedules helps improve adherence, reduces stress, and supports consistent results.

Panelists underscore that safety, simplicity, and sustainability are the pillars of successful long-term care. Empowering caregivers with easy, safe options fosters trust and consistency in treatment.


Panelists discuss how low systemic absorption and simple dosing schedules improve safety, adherence, and caregiver confidence in pediatric AD care.

Shanna Miranti, MPAS, PA-C

Articles